Virbac has launched Neoprinil, an eprinomectin pour-on solution indicated for use against internal and external parasites in cattle, including gut and lungworms, mange mites, sucking and chewing lice, horn flies and warbles.
Neoprinil has a zero-day withdrawal period in milk and can be administered using the company's Farmpack and Flexibag.
The Farmpack is a backpack which holds a Flexibag of Neoprinil solution. The Flexibag is a bag designed to protect medication and preserve it once it has been opened. The two together were awarded the 2014 PharmaPack Award for Innovative Packaging.
Neoprinil offers a one year stability period once it has first been opened and requires no special conditions for storage. It is presented in 2.5L, 4.5l and 8l pack sizes.
Product Manager for Large Animals Brigitte Goasduf MRCVS said: "A high worm burden can have adverse effects on the herd's productivity and performance and so it is advisable to ensure infected animals are treated as part of a Herd Health Plan. Eprinomectin is a tried and trusted parasiticide and studies confirm that it can have a positive impact on both milk production and on weight gain. Its zero day withdrawal period is a major benefit for dairy farmers.
"With the launch first of Deltanil and, now, Neoprinil, we are reinforcing our commitment to work with veterinary surgeons and farmers to understand the everyday challenges they face and to provide practical, effective solutions. We offer a comprehensive parasiticide range with a dispensing system that sets a new standard for convenience and ease of use."
Fluboral controls gastro-intestinal nematodes including Ascaridia galli (adult stages), Heterakis gallinarum (adult stages) and Capillaria spp. (adult stages) in chickens and Ascaris suum (adult and L4 intestinal stages) in pigs.
Dechra says Fluboral’s formula allows it to mix in drinking water quickly and easily with five seconds of stirring.
Fluboral has a guaranteed 24-hour stability without sedimentation of the suspension after dilution in drinking water and Dechra says there is no risk of inhomogeneous mixing.
Johnny Wells West, key account manager – pig and poultry at Dechra, said: “Fluboral is a welcome addition to our Solustab range of water-soluble products, providing effortless and efficient parasite control in drinking water to enable farmers and producers to start medication quickly and cost-effectively, as and when needed.”
https://www.dechra.co.uk/products/livestock/prescription/fluboral#Fluboral.
Procapen contains a high dose of procaine benzyl penicillin, a narrow spectrum antibiotic which targets the most important pathogens in fresh cases of mastitis in cows and is the drug of choice against benzylpenicillin-susceptible streptococci and staphlococci.
Marcus Scott, Large Animal Business Manager at Forte said: "With the widespread shortage of intramammary tubes at the moment, Procapen provides a welcome solution for many mastitis cases."
For more information, contact your local Forte Territory Manager or email: enquiries@fortehealthcare.com.
The RCVS Disciplinary Committee has suspended a Cardigan veterinary surgeon from the RCVS Register for five months, for failure to perform accurate bovine tuberculin testing and for falsely certifying the test results.
During the two-day hearing, Dewi Wyn Lewis, of Priory Veterinary Ltd, Cardigan, answered charges about inaccurate skin fold measurements and false certification relating to two visits he made as an Official Veterinarian to a farm in April 2009 to undertake tuberculin testing.
Mr Lewis accepted that he had not carried out the tuberculin tests in the way required by Animal Health (AH) - an Executive Agency of the Department for Environment, Food and Rural Affairs - and had taken short cuts to save time. However, he denied the charges, arguing that, although instructions to Official Veterinarians clearly required the use of callipers to measure the skin folds of cattle necks on Day One of testing, not using callipers and using his finger and thumb did not amount to failing to measure.
He also argued (and it was accepted by the Committee) that, regarding Day Two of testing, there was inconsistency in AH's instructions on calliper use, which in written form required using callipers for measuring every animal but in practice accepted use of callipers when a reaction could be detected by manually palpating the skin. On Day Two, Mr Lewis said, he had done what AH required: he had used callipers on the cattle he identified for closer examination.
The Committee, however, found that by failing to use callipers on the first day, as required by AH, Mr Lewis had failed to measure the skin folds of almost all of the 104 cattle. The Committee was also satisfied that, on the second day, 10-20% of the herd were not even touched by Mr Lewis and the Committee accepted the evidence of the three other witnesses present during the testing, which indicated that Mr Lewis had failed to carry out careful assessment and manual palpation of every animal.
The Committee then considered whether Mr Lewis had dishonestly signed the certificate, or had signed a false certificate which he ought to have known was inaccurate. The Committee noted that there were no previous Disciplinary findings against Mr Lewis, and was prepared to believe his assertion that, although he knew he had not carried out the tests in strict compliance with AH's instructions, he genuinely believed his methods to be at least as accurate as measuring with callipers and did not think he was doing anything wrong or dishonest. The Committee could not then be sure that Mr Lewis had realised what he was doing was dishonest. However, the Committee noted that 'false' also means 'inaccurate' and, as Mr Lewis ought to have known that as his testing methods were not adequate, he also should have known that a considerable number of measurements on the certificate were inaccurate and that the certificate itself was inaccurate.
After considering the facts of the case, the Committee concluded that Mr Lewis's actions amounted to serious professional misconduct and directed that he should be suspended from the Register for five months, after which he may return to practice. In relation to the sanction, the Committee said: "In reaching this decision it is relevant that the false certification was not dishonest and that there was professional and personal mitigation put forward on behalf of Mr Lewis. The Committee has paid regard to the fact that Mr Lewis is an experienced veterinary surgeon who is highly thought of in his local area. It does not believe that there is any likelihood that he will repeat his previous conduct."
The Committee also said it gave considerable weight to the fact that Mr Lewis had had to wait an additional three-month period for the hearing because of an earlier adjournment.
Zoetis has launched a one-dose vial of Rispoval IntraNasal, in order to offer respiratory health protection in calves as soon as possible after birth without either waiting to batch them in groups or wasting unused vaccine in multi-dose packs.
To make ready for use, the vaccine is reconstituted by mixing a powder with sterile diluent. Once mixed, the licensed shelf life is two hours. This means any that is unused in multi-dose packs must be thrown away. By stocking a combination of one- and multi-dose packs, farmers can eliminate this.
The vaccine protects against two primary viral causes of pneumonia in young calves, BRSv and Pi3v1. Surveillance of blood samples from 2,145 calves with pneumonia signs found 78% exposed to BRSv, 81% to Pi3v2. The product licence allows use from nine days of age, with onset of immunity to BRSv and Pi3v after five and 10 days respectively. The licence also specifies a duration of immunity of 12 weeks.
Zoetis vet Carolyn Hogan says that viruses are the instigator of a majority of respiratory health problems: "Early-life protection also helps reduce the threat from opportunistic secondary bacterial infections, such as Pasteurella.
"Good respiratory health is essential to ensure calves develop to achieve their lifetime potential. But it's estimated that 67% of pneumonia cases occur in calves less than three months of age3.
"Whether suckled or reared, calves that don’t grow effectively in the early weeks are unlikely to catch up later. On both dairy and beef units, proactive management of the calf living space, nutrition and disease resilience is critical to maximise lifetime productivity, which is clearly so important under today's farm business economics.
More information about the benefits of managing respiratory health in calves is available at plantoproduce.co.uk.
The draft code contains twenty recommendations to seek veterinary advice on the subject, compared to ten in the previous version, highlighting the crucial importance of veterinary surgeons' involvement in the welfare of meat chickens.
The new codes have been welcomed by the BVA, the British Veterinary Poultry Association (BVPA) and Veterinary Public Health Association (VPHA), who jointly responded to the Government consultation on the updating of the codes.
BVA President John Fishwick said: "We welcome the Government’s recognition of the vital role the veterinary profession plays in poultry welfare, with further references throughout the updated draft code to the importance of seeking veterinary advice.
"We are particularly pleased to see the recommendation that welfare outcomes should be used to assess and monitor the ongoing welfare of the birds as part of the farm health and welfare plan, and with the signposting to the Humane Slaughter Association’s Poultry Catching and Handling Technical Note within the code.
"The British poultry industry already has some of the highest welfare standards in the world and the veterinary profession and poultry industry will continue to work with Defra on further enhancing animal welfare codes to reflect best industry practice."
The draft code was placed in Parliament on 9 January 2018. If there are no objections from Parliament, it will come into force in March 2018.
Photo: Flock of Chickens (Gallus gallus domesticus) Roaming Freely in Front of Chicken Sheds on a Farm in the Rural Village of Chenson, Devon. Shutterstock / Peter Turner Photography
In the study, the Pirbright - Wageningen research team combined their expertise in both FMDV and mathematical modelling to evaluate the methods and effects of preclinical diagnosis during surveillance (as would be in place during an outbreak), in order to reduce the risk of transmission between herds of cattle on neighbouring farms.
Transmission experiments in cattle were used to collect samples taken from individual animals such as blood, saliva and nasal swabs, and at herd level such as air samples, on a daily basis during the course of infection. The sensitivity of each of these types of samples for the detection of infected cattle during different phases of infection was then quantified.
Dr. Simon Gubbins, Head of Transmission Biology at Pirbright said: "Our results were incorporated into a mathematical model for FMDV transmission in a cattle herd in order to evaluate the impact of early detection and removal of an infected herd on the reduction in the amount of infectious output which could enable transmission of the virus to cattle on a neighbouring farm.
"By using weekly surveillance, clinical inspection alone was found to be ineffective at blocking transmission. This was in contrast to the impact of weekly sampling using saliva swabs of at least ten animals per farm or daily air sampling (for housed cattle), both of which were shown to reduce the risk of transmission substantially."
Dr. José Gonzáles from Wageningen Bioveterinary Research added: "These findings provide a new approach to disease control which could be added to our emergency preparedness programmes. A potential benefit of applying this strategy is a reduction in the number of animals culled unnecessarily, which is likely to happen when traditional strategies such as pre-emptive culling are implemented."
Following these initial results, the Pirbright - Wageningen research team plan to take their approach from the controlled conditions of the laboratory and test it in field trials. If successful, they hope it will help to reduce the social and economic impact of one of the world’s most devastating livestock diseases.
The campaign, taking place in February, will underline that responsible use of antibiotics starts with newborn calves, lambs and piglets receiving the right amount of colostrum within a couple of hours of birth – something all farmers have the potential to achieve.
A number of organisations will be releasing information and promoting best practice throughout the month, mainly based around getting the 3Qs (quality, quantity and quickness) of colostrum delivery right.
The FarmAntibiotics.org information website will be signposting to these resources, as well as highlighting hints and tips for more effective colostrum management.
RUMA chairman Gwyn Jones says that as a farmer, he recognises the pressures at lambing and calving, and just how easy it can be to take shortcuts with the all-important first feed.
"But it was a wake-up call when I found out calves receiving insufficient colostrum at birth are more than twice as likely to develop respiratory disease, and can have mortality rates as high as 13%," he said.
"Too often we see the animal start to suck or we give it a feed, and don’t think about the actual quantity of colostrum it consumes immediately after birth.
"All these factors have an enormous impact on the levels of antibodies in the bloodstream 24 hours later, and on the subsequent health of the animal and its need for antibiotic treatment during its whole life.
"Better colostrum management is an incredible opportunity – not just to ensure better health for the future, but to cut antibiotic use and produce a more valuable animal for onward rearing."
Research manager Dr Jenny Gibbons from AHDB says their recent 'Calf to Calving' campaign focusing on youngstock rearing has seen nearly 40% of attendees go on to buy equipment to test the quality of colostrum.
Jenny said: "With recent figures from the Royal Veterinary College indicating just 31% of dairy farmers have been testing the quality of the colostrum before feeding it, this uptake is good news.
"Another area to tackle is time of feeding. Only 5% are feeding within the ideal two hours after birth. Changing these practices would make a huge difference to calves for onward beef rearing as well as replacement heifers."
Specialist sheep vet Dr Fiona Lovatt says lambs receiving insufficient colostrum at birth is behind one of the sheep industry’s biggest antibiotic use 'hotspots', in what is otherwise a low-use sector.
She said: "It’s largely avoidable. The reality is that we simply don’t see Watery Mouth in lambs that have taken sufficient colostrum on board in that golden 24-hour window immediately after birth."
Fiona says a 5kg lamb at birth needs 1 litre of colostrum in its first 24 hours of life to give it essential levels of natural immunity, but importantly, the first feed should be within two hours of birth.
"Antibodies – essential in protecting against all disease including E coli infections – cannot cross through the placenta, so must be transferred through colostrum.
"While thin ewes or those that are not well fed in the run-up to lambing will produce too little colostrum of low quality, more often it’s simply not getting enough colostrum into the lamb quickly enough after birth."
Fiona says the sheep sector should not be relying on use of preventative antibiotics – because of image but also the very real problem of antibiotic resistance. "We know from government data that 50% of neonatal lamb E coli are already resistant to spectinomycin, the most commonly used dose. We need to protect these antibiotics, or we will lose them."
Veterinary lead at AHDB and pig specialist Dr Mandy Nevel says baby pigs need colostrum too, to maintain body temperature as well as protect them against disease.
Mandy said: "Baby pigs are born wet and with very little energy reserve. Ideally they need to get a feed in within the first 30 minutes to prevent hypothermia. This early feed will also provide essential immunity, giving them the best chance of survival in their first few weeks of life.
"Sow vaccination is the best way to boost antibody levels in the colostrum. That is why piglets who receive good levels of colostrum early will also be the healthiest at weaning. That extra care in the first hours of life will really make a difference."
Mandy includes post-weaning diarrhoea and respiratory disease as longer term threats for piglets receiving insufficient colostrum at birth. "Colostrum really is a golden opportunity to secure lower antibiotic use and a healthier animal for its whole life."
Veterinary surgeons and farmers looking for more information should search for the #ColostrumIsGold hashtag on Twitter, or go to the FarmAntibiotics.org website to be signposted to tools, resources and case studies from 1 February.
Merial is highlighting the results of an independent study published in July's Journal of Dairy Science which showed that treating acutely lame cows with the non-steroidal anti-inflammatory (NSAID) Ketofen (ketoprofen), alongside therapeutic trimming and the application of a block, resulted in a significantly better recovery rate compared to the other treatment protocols used.
In the study, Evaluation of treatments for claw horn lesions in dairy cows in a randomised controlled trial by Thomas et al1, 56% of the cows in the above treatment group were observed to be sound.
Sioned Timothy, Merial Technical Veterinary Manager (pictured right) said: "The lack of evidence to underpin a standardised approach to treating lameness in cattle has previously been highlighted2.
"This study demonstrates the value of using an NSAID as part of lameness treatment both for its welfare benefits, and also to reduce the impact of lameness on herd productivity through improved recovery rates. It also highlights the importance of implementing herd health protocols that focus on early intervention – identifying cows as soon as they become lame should be a priority for dairy farmers. With lameness cited as having a significant adverse effect on milk yield3 and cull rate in the herd, a proactive approach to lameness control is critical. Farmers should work with their vets and foot trimmers to ensure that when lame cows are identified they are treated in the most effective way.”
Sioned added: "The importance of routine mobility scoring cannot be underestimated. Clinical lameness has been shown to cause a decreased milk yield from up to four months before diagnosis 3, which can translate to a mean reduction of 357 litres per 305 day lactation. Furthermore, the impact on fertility and the long term impact on replacement is also acknowledged, with lame cows less likely to conceive and having an increased risk of conception failing."
References
Latest figures from the Food Standards Agency (FSA) indicate that 22% of sheep and goats (3 million) are not stunned before slaughter1.
This is an increase from 2013 when it was estimated 15% (2 million) of sheep and goats were slaughtered without stunning.
At the same time, in a response to a parliamentary question2 from Kerry McCarthy MP (Bristol East), Defra has admitted that it does not hold data on how much of this non-stunned meat is exported.
The BVA says a recent trade deal with Saudi Arabia could greatly increase the exports of British lamb and other meat, some of which may be from non-stun slaughter. Information on the lamb market also indicates that exports in general (especially to non-EU countries) are on the increase, with total export volumes up 14% in 2017 and non-EU volumes growing to 5,400 tonnes – up two-thirds on the previous year3.
The BVA is calling for the timely provision of information on non-stun exports, firstly to ascertain the extent to which the UK is exporting meat from these sources and secondly to inform potential measures to ensure supply matches rather than exceeds domestic demand.
Other EU countries that allow non-stun slaughter have measures in place to limit the export of non-stun meat to help ensure that meat killed by this method is for the domestic market. For example, Germany requires that abattoirs apply for a licence by defining the number of animals to undergo non-stun slaughter to meet local demand only.
BVA President, John Fishwick, said: "Each year millions of animals in the UK are not stunned before slaughter and BVA will continue to push for an end to non-stun slaughter in the interests of animal welfare. The latest FSA figures suggest that a sizeable proportion of sheep and goats that are slaughtered in the UK are done so without stunning and that this seems to outstrip the requirements of the religious communities who consume meat that has been slaughtered in this way.
"It is difficult to unpick the possible factors that contribute to this mismatch but an essential step to understanding this better would be to provide data on how much, if any, non-stun meat is exported abroad. With Brexit on the horizon and in the light of announcements about export deals with non-EU countries, there is a pressing need for clarity on the quantities and destinations of exports of non-stun meat.
"While not illegal, if meat from non-stun religious slaughter is exported we consider this to be outside the spirit of the legislation which allows non-stun as a derogation from the law to meet the needs of religious communities."
The new website explains what Veterinary Specialists are, how they may be able to help, and how the referral process works. The BCVSp says it has been designed to be a useful resource which primary practices can direct their clients to if a referral is being considered.
As well as being able to search for a Specialist by location and by discipline, owners can also read some real life patient case studies following the referral, treatment journeys and outcomes of animals that have benefited from Specialist care and meet some of the Specialists via podcast links.
BCVSp Trustee Celia Marr said: "While most happy healthy animals will never need Specialist veterinary care, if they do we want their owners to know that we are here to help.
"There are many hundreds of Specialists working at the forefront of veterinary care and also those working in research, pathology and academia, helping to advance animal health and welfare, every day. We believe our new website should help to spread the word and make referral more understandable and accessible."
Visit the new website at www.yourvetspecialist.org
Intervet/Schering-Plough Animal Health has launched a new cattle and sheep vaccine which it says gives vets an additional opportunity to prescribe the broadest possible protection against clostridial diseases.
Bravoxin 10 is a low dose clostridial vaccine containing antigens for protection against C. perfringens type A, C.perfringens type B, C.perfringens type C, C.perfringens type D, C.novyi type B, C.septicum, C.tetani, C.sordellii, C.haemolyticum and C.chauvoei.
Dosage volumes are 2ml for cattle and 1ml for sheep and the new vaccine can be used in animals from as young as two weeks old if the dam has not been previously vaccinated. A booster dose pre-calving or lambing will also deliver 8-12 weeks passive immunity in calves and lambs (apart from against C.haemolyticum).
Intervet/Schering-Plough Animal Health ruminant veterinary adviser Rosemary Booth MRCVS said: "Clostridial bacteria take the lives of cattle and sheep on a regular basis and are the cause of a significant proportion of the sudden livestock deaths in this country. In 2007, an independent survey of over 500 UK dairy and beef farmers revealed that half the interviewees had experienced calves or adult cattle dying for no apparent reason. The reality is that many of these losses could have been due to clostridial diseases. Farmer respondents valued the livestock loss at anywhere between £505 and £1243 per animal. Even at the lowest stock valuation, preventing the loss through broad-spectrum vaccination would pay for nearly five years of Bravoxin 10 use in a 100 cow herd.
"Now that additional clostridial pathogens such as C. sordellii and C. perfringens A have been recognised by the VLA and SAC as significant causes of deaths on both cattle and sheep farms, it makes sense to widen pathogen cover on some ruminant livestock units. Bravoxin 10 allows practitioners to prescribe the broadest possible disease protection."
The sheep industry already understands the importance of broad-spectrum vaccination against clostridial diseases, but Iain Carrington from Intake Veterinary Services based in Northumberland believes cattle producers should also upgrade their protection.
"There was a time that clostridial disease control in cattle meant vaccinating your youngstock against blackleg at turnout, or discovering dead animals and then reacting with blackleg vaccine," he said. "But over the last few years, I have seen an increased incidence of different clostridial diseases in far from typical circumstances.
"There are also a large number of cattle deaths going undiagnosed and it is likely that many are caused by clostridial species. As a result, we are now advising many of our clients to take a broader-spectrum vaccination approach to ensure adequate protection - not only of the cows themselves - but also their calves through good colostral transfer," he said.
Bravoxin 10 is a prescription-only medicine (POM-V). For further information, contact the Intervet/Schering-Plough Animal Health Veterinary Support Group on 01908 685685.
Rexxolide contains 100 mg/ml of tulathromycin, which is widely used to treat BRD and SRD. It also has a single dose and low injection volume of 1 ml/40 kg BW, to make it more convenient.
Dechra says Rexxolide has an immune-modulating and anti-inflammatory action and offers equal viscosity and syringability as other products on the market1. It can be used for treatment and metaphylaxis of BRD and SRD and offers early-stage treatment for infectious pododermatitis.
Dechra’s Equine and Food Producing Animal Brand Manager, Emma Jennings said: “Launching Rexxolide into the market provides an alternative option to existing BRD, SRD and foot rot treatments for farm vets across the UK and Ireland.
"We support an integrated approach to the control of BRD, with good husbandry, early detection and correct therapy being vital tools in managing the multi-factorial condition."
Rexxolide is available in 50ml and 100ml vials. For more information visit www.dechra.co.uk.
SPVS is leading a ground-breaking new project which aims to find out how veterinary surgeons are treating a range of clinical conditions.
Two hundred practitioners are being sought to provide details of how they address clinical conditions in three study areas: small animal, equine and farm animal, on a new website: www.howdoido.org. The findings, which will be made anonymous, will eventually form the basis of a clinical benchmarking process, which will tie in with the growing trend towards evidence-based medicine.
SPVS's objective is to understand and support how clinicians work in practice and approach particular clinical cases. The Society is working alongside Dr Mark Johnson who carried out the Confidential Enquiry into Perioperative Equine Fatalities.
SPVS Junior Vice President Jacqui Molyneux said: "This is an exciting new study which will shed a lot of light on what we as clinicians are doing in practice with the eventual aim of developing a clinical benchmarking process.
"The project however will only be worthwhile if a significant number of practitioners take part, so we're encouraging vets to visit the website and find out more. It will take no longer than ten minutes to fill in each clinical case."
There are three awards on offer: two ruminant bursaries and one companion animal bursary. Applications must be in by 30th November 2018.
Each project should be completed within one to two years and the vet practitioner proposals will be judged by university academics to ensure independent assessment.
The companion animal research bursary will be assessed by the University of Nottingham Centre for Evidence-based Veterinary Medicine and the ruminant research bursary applications will be assessed by academic staff from the University of Bristol School of Veterinary Science.
Michelle Townley, veterinary advisor at MSD Animal Health (pictured right) said: "New knowledge and good research skills form the lifeblood of the industry so we’re keen to get as many applications as possible as part of our commitment to encouraging research in the veterinary industry."
For further details go to the MSD Animal Health Research Bursary website: www.msdahresearchbursary.co.uk.
CEVA Animal Health has launched Marbokem, a Marbofloxacin-based antimicrobial for the treatment of respiratory disease in cattle which offers the advantages of a one-shot protocol and a shock-resistant vial.
Marbokem is used for the treatment of respiratory infections caused by sensitive strains of Pasteurella multocida, Mannheimia haemolytica and Histophilus somni. CEVA says Marbofloxacin's efficacy has been proven in terms of re-treatment rate, success, speed of action and MICs in comparison with many frequently used quinolones and macrolides. (1,2,3,4)
According to CEVA, Marbokem's one shot protocol means it's quick and economical to use, while its presentation in an ergonomic CLAS vial makes for light and shock-resistant handling, resulting in fewer breakages and reduced costs. The company says Marbokem is also very competitively priced.
For further product information, please contact CEVA Animal Health Ltd, 90 The Broadway, Chesham, Bucks, HP5 1EG, telephone 01494 781510 or visit the website at http://www.ceva.uk.com/
1 Grandemange, E., Fournel, S., Woerhle, F. (2009) Field evaluation of the efficacy of 2 antibiotics in treating bovine respiratory infections. Poster, Journées Nationales des GTV, Nantes, France. 2. Grobbel, M., Lübke-Becker, A., Wieler, L., Froyman R., Friederichs, S., Filios, S. (2007) Comparative quantification of the in-vitro activity of veterinary fluoroquinolones. Veterinary microbiology 124 (73-81). 3. Roy, O., Pillet, F., Heurtin-Vallé, A., Frontczak, N. (2008) Comparative field clinical efficacy of a single intramuscular injection of marbofloxacin in the treatment of bovine respiratory disease. Poster, World Buiatrics Congress, Budapest, Hungary.4. Wu, C. (2004) Determination of minimum inhibitory concentrations of danofloxacin and other commonly used cattle antimicrobial agents against Mycoplasma bovis isolated from cattle with clinical disease. Le médecin vétérinaire du Québec. 34 (1-2).
Vets and farmers must do more to improve dairy cow welfare in the UK, according to the British Veterinary Association (BVA). The call comes after careful consideration of major reports and opinions on the welfare of dairy cattle by FAWC (Farm Animal Welfare Council) and EFSA (European Food Safety Authority).
In a new policy statement, released last week, the BVA outlined the need for veterinary surgeons to take an active role in educating farmers and promoting better welfare, as well as working with farming clients towards a 'Herd Welfare Plan' that can be followed alongside the 'Farm Health Plan'.
The BVA says it recognises that some improvements have been made in certain welfare areas, such as longevity, but that issues relating to lameness, mastitis, housing and infectious diseases, such as TB, continue to be of concern.
Veterinary surgeons are well placed to offer help and advice in order to educate farmers on welfare aspects and how they affect herd health, productivity and ultimately, profit.
The policy also addresses issues around breeding for certain traits, which should always be discussed with a vet through a breeding plan, and the challenges of housing dairy herds. The BVA believes much can be done to achieve high welfare standards through good housing.
Finally, the BVA supports retailers who reward farmers financially for improving welfare standards for dairy cows and their calves.
Professor Bill Reilly, President of the BVA, said: "Recent reports have highlighted a number of major concerns about the welfare of dairy cows and their calves, and the BVA feels strongly that vets can take a leading role in addressing these issues.
"Lameness, mastitis, inadequate housing and infectious disease can all lead to poor welfare. Not only is this unacceptable for the animals, but it can be bad for the farmer's business.
"By working together, vets and farmers can and should do more to improve dairy cow welfare through Herd Welfare Plans, breeding plans and improved housing conditions."
Keith Cutler, President of the British Cattle Veterinary Association (BCVA), added: "While the UK enjoys higher standards of dairy cow welfare than many other countries, there are still some issues that need to be tackled.
"Vets and farmers need to work together to address problems. In my experience most farmers are pleased to discuss issues with their vets and then work in conjunction to improve the health and welfare, and ultimately the productivity and profitability, of their herds."
The Health Products Regulatory Authority (HPRA) has also granted a marketing authorisation in exceptional circumstances (Article 25, 26 EU Reg 2019/6) for Bultavo 3 in Ireland.
The company says that so far, more than 40 million doses of Bultavo 3 have been distributed in Europe to help limit the spread of BTV-3.
Boehringer points to a recent field study published by the German reference laboratory Friedrich-Loeffler-Institut (FLI), which showed that vaccination of sheep and cattle with Bultavo 3 induces immunity against the virus1.
According to the study, animals vaccinated with Bultavo 3 consistently showed evidence of a protective antibody response to BTV-3, although animals vaccinated with other BTV-3 vaccines did not1.
Boehringer says it is now compiling the data needed to obtain a full marketing authorisation in accordance with Article 8 of EU Regulation 2019/6.
Reference
Tri-Solfen contains lidocaine and bupivacaine to deliver rapid onset and prolonged local anaesthesia, adrenalin to reduce blood loss and cetrimide to lower the risk of infection.
Dechra says the gel is effective in 30 seconds, making it a practical tool to improve animal welfare via cutaneous and epilesional use.
Tri-Solfen was originally developed and launched in Australia by Medical Ethics, a company that specialises in pain management treatments for humans and animals.
According to the company, more than 100 million animals have been treated with Tri-Solfen in Australia, New Zealand and Portugal, where it is licensed for disbudding, dehorning, castration and general wound treatments in cattle, sheep, pigs and horses.
www.dechra.co.uk
They say this approach could lead to a reduction in the number of vaccines that need to be administered to each bird.
Vaccines that target multiple diseases are in high demand due to the many viruses that can circulate simultaneously in flocks. Protecting against the most dangerous diseases with one vaccine could reduce overall vaccination costs for poultry producers and decrease the number of times that birds need to be handled.
The researchers demonstrated that a gene editing system called CRISPR/cas9 can be used to insert a gene of the IBD virus into the currently used Marek’s disease vaccine virus. The added genetic material protects poultry against IBD in addition to the protection already offered by the Marek’s disease vaccine, meaning that bird owners would only need to use one vaccine instead of two.
Other vaccines generated by conventional methods can achieve a similar result, but by using the CRISPR/cas9 system the Pirbright researchers say they have been able to insert the IBD gene far more quickly, easily and accurately than the methods that have been used before. This will significantly reduce the time needed to generate new vaccines.
Professor Venugopal Nair, joint leader of the research at Pirbright said: "The method we have created with CRISPR/cas9 really increases the scope of how we edit the Marek’s disease vaccine to include other virus components. Now we have shown that the gene-edited vaccine protects against both Marek’s disease and IBD, we are looking at inserting more genes from other viruses."
The team intend to generate a vaccine that will be able to protect against multiple avian diseases and will next target two high consequence poultry viruses - avian influenza virus and the Newcastle disease virus. The flexibility of the new method also means that as the viruses evolve, the vaccine virus can be easily edited to include new genes which protect against emerging strains.
The Pirbright Institute says there has been huge commercial interest in using this technology to develop novel vaccines, so it intends to partner vaccine manufacturing companies to bring CRISPR/cas9 edited vaccines to market.
This scientific paper can be found in the Vaccine journal and was funded by the Biotechnology and Biological Sciences Research Council (BBSRC); grant numbers BB/P016472/1 BB/L014262/1.
Photo: Cells infected with the Marek's disease vaccine virus, HVT, (green) expressing the inserted infectious bursal disease virus gene, VP2 (red). Cell nuclei are shown in blue. © Dr Na Tang, The Pirbright Institute 2018.
Intervet/Schering-Plough Animal Health has announced the launch of PORCILIS AR-T DF, an inactivated vaccine against progressive atrophic rhinitis in piglets with a new adjuvant which the company says is associated with fewer injection site reactions.
PORCILIS AR-T DF uses DILUVAC FORTE (DF), an aqueous vitamin E-based adjuvant and will replace PORCILIS AR-T, a similar vaccine containing an oil-based adjuvant. The newly formulated vaccine is approved to reduce the clinical signs of progressive atrophic rhinitis in their offspring. Progressive atrophic rhinitis is caused by a toxin from the bacteria Pasteurella multocida affecting bone-forming cells in the snout of the young piglet.
Marc Dickie, Senior Director, Global Swine Business Unit at Intervet/Schering-Plough Animal Health said: "The innovative PORCILIS AR-T DF vaccine combines the proven efficacy of the current PORCILIS AR-T with an improved safety profile and convenience for the veterinarian that is offered by the aqueous DILUVAC FORTE adjuvant. The new vaccine also demonstrates the commitment of our company to continuously improve our vaccines, thereby offering value-added benefits to our customers."
A new injectable antibiotic with nil-milk-withhold licensed to treat foul-in-the-foot in a single shot has been launched by Pfizer Animal Health.
Naxcel Cattle's active ingredient is ceftiofur in a patented sustained-release formulation. According to the company, one injection provides a full course of antibiotic therapy, giving seven days of therapeutic blood levels against the majority of inter-digital necrobacillosis ('foul-in-the-foot') pathogens.
Pfizer vet Dave Gilbert says the expectation is that Naxcel Cattle will make on-farm therapy easier and help improve treatment compliance and thereby first treatment success rates, compared to treatments which require repeat injections. "Having the full course in a single injection simplifies treatment protocols and eliminates a number of reasons for non-completion of treatment, such as forgetting a second or third dose, or not giving them because of apparent symptomatic recovery from the condition."
The site of injection for Naxcel Cattle is the subcutaneous area at the base of the ear (see Figures 1 & 2). Injection instructions are supplied in the product pack. Dave Gilbert suggests that provided cattle are adequately restrained during administration the injection technique is simple and straightforward. The dose rate is 1ml/30kg body weight and up to 30ml can safely be given into each site.
Figure 1. Subcutaneous administration of Naxcel Cattle at the posterior aspect of the ear where it attaches to the head (base of ear).Figure 2. Injection location for the subcutaneous administration of Naxcel Cattle at the posterior aspect of the ear where it attaches to the head (base of ear).
BVA President Harvey Locke used his annual London dinner speech last night to urge the Government to take action on veterinary student fees and the welfare of dogs, and respond to the consultation on dangerous dogs.
Guests at the dinner included The Rt Hon Caroline Spelman MP, Secretary of State for Defra, parliamentarians, veterinary surgeons, and representatives from the agri-food industry, pet industry, welfare charities, research and veterinary education.
Mr Locke began by raising concerns over cuts to animal health and welfare and disease surveillance budgets: "In the Comprehensive Spending Review Defra took one of the biggest hits. The profession remains deeply concerned that cuts in research and development and disease surveillance could have catastrophic consequences. Right now the UK enjoys some of the highest animal health and welfare standards in the world and so it is in all of our interests to ensure the viability of the farming sector amidst massive competition from abroad, where those standards may not always be as high."
On veterinary student fees, Mr Locke outlined the 'double whammy' of a long course and compulsory Extra Mural Studies in the holidays: "Our role as the guardians of animal health and welfare faces an uncertain future following the announcement that the cap on tuition fees will be raised to between 6 and 9 thousand pounds a year. We fear this could have a huge impact on the decisions of A-level students, with fewer and fewer opting for an expensive veterinary science degree.
"Although the plans are not yet finalised we are bracing ourselves for veterinary degrees, which are costly to run, to be priced at the top of the scale, meaning veterinary students of the future will graduate with at least £45,000 of debt in tuition fees alone. Faced with these levels of debt, our concern is that those who do make it to graduation won't opt for the food animal practice and public health roles that attract smaller pay packages. We need to think carefully about how we can secure the future provision of large animal practitioners."
On companion animal issues Mr Locke asked Defra not to defer all decisions on dog welfare to the newly-formed Dog Advisory Council: "While the BVA fully supports the Advisory Council, we would urge the Government not to use it to delay decisions that might improve the health and welfare of dogs now. At a recent meeting of the Associate Parliamentary Group on Animal Welfare (APGAW) ...there was overwhelming support for provision for healthy breeding to be brought into Defra's welfare codes.
"We have long maintained that to ignore breeding in the dog welfare code is a serious oversight by Defra. In England we already have regulations that protect our farmed animals from breeding procedures that cause suffering or injury, but not for our pets. This contradictory approach makes little sense. Updating the welfare codes to include breeding would send a clear message that the Government is committed to improving the health and welfare of man's best friend."
On dangerous dogs Mr Locke renewed the BVA's call for the Government to respond to the Defra consultation, which found 77% in favour of scrapping breed-specific legislation: "Despite this overwhelming call from the public, the Government has kept its powder dry, repeatedly promising to announce its response soon.
"Secretary of State I would like to assure you that the BVA is prepared to work with all of the other organisations with an interest in dog welfare and public safety to find an effective solution. We all want to see people protected on private property; legislation that targets irresponsible owners and not just the way a dog looks; and tools that allow the police and other enforcement agencies to act swiftly to protect the public.
"And, crucially, we all want to work with you to achieve these aims."
Metaxol contains 20 mg trimethoprim and 100 mg sulfamethoxazole per ml and can be added directly to drinking water or used in a concentrated stock.
The new product, which is part of the company's SoluStab range, replaces Methoxasol. Dechra says it is likely to be welcomed by farmers wanting to target entire flocks because of its shorter withdrawal time for broilers.
Dechra Brand Manager Emma Jennings said: "Sulfamethoxazole is a potent sulfonamide and, when combined with trimethoprim, it has a synergistic and bactericidal effect.
"Both active ingredients are rapidly absorbed and distributed widely in tissues making it a highly effective treatment.
"The shorter withdrawal time for broilers will make it an attractive treatment for farmers wanting to target entire flocks."
Metaxol is not suitable for laying hens.
In fattening pigs, Metaxol is suitable for the treatment and metaphylaxis of post-weaning diarrhoea caused by beta-haemolytic K88-positive, K99-positive or 987P Escherichia coli strains susceptible to trimethoprim-sulfamethoxazole.
It can also be used for secondary bacterial infections caused by Pasteurella multocida, Actinobacillus pleuropneumoniae, Streptococcus spp. and Haemophilus parasuis susceptible to trimethoprim-sulfamethoxazole.
In broilers, it can be used for treatment and metaphylaxis of Colibacillosis caused by Escherichia coli susceptible to trimethoprim-sulfamethoxazole or Coryza caused by Avibacterium paraga.
The recommended dosage is 0.25 ml of product per kg body weight per day for four to seven days for pigs and 0.38 ml of product per kg body weight per day for three days for chickens.
For support in calculating dosages, visit http://calculator.solustab.eu/.
Located in the South East of England, the centre is part of the new School of Veterinary Medicine at the University of Surrey, and one of the UK's largest veterinary pathology centres, offering high-containment post-mortem examination facilities and histopathology.
The centre is staffed by a team of board-certified veterinary pathologists, veterinary investigation officers and technicians, with expertise in farm-animal, equine, exotic and small-animal pathology.
The new building centres on a large containment level 2 post-mortem examination room with high ceilings, natural lighting, post-mortem examination tables, biological safety cabinets and integrated cold rooms, all served by a powerful winch system which means that post-mortem examinations can be performed on a wide range of species. A viewing gallery overlooks the suite and post-mortem examinations can be recorded and streamed for training purposes.
Professor Roberto La Ragione, Director of the Veterinary Pathology Centre, said: "Veterinary pathology is a growing discipline and its importance has been highlighted in recent disease outbreaks and the important role veterinary pathologists make in drug development. Helping the farming community to be more effective, sustainable and innovative, the Centre will work with partners, businesses and researchers to address some of the unique challenges faced by the veterinary and scientific community.
"It is the close relationships with our external clinical and scientific partners that enables us to be innovative in our approach to education and training here at the Surrey. An example of the latter is the use of digital pathology in teaching, research and diagnostics, which was the subject of discussion at the recent launch of the Veterinary Health Innovation Engine (vHive).
"Together with our partners such as the National Physical Laboratory and the 5G Innovation centre, the Centre is at the forefront of the digitalisation of pathology and innovative big data management.
"The Centre offers the opportunity to inspire the next generation of veterinary pathologists and complements the centres of excellence that already exist in other vet schools and research institutes."